{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:43:56Z","timestamp":1788536636068,"version":"build-2803163510"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["81860035"],"award-info":[{"award-number":["81860035"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010857","name":"Jiangxi Provincial Department of Science and Technology","doi-asserted-by":"publisher","award":["20203BBGL73210"],"award-info":[{"award-number":["20203BBGL73210"]}],"id":[{"id":"10.13039\/501100010857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> The introduction of Bruton\u2019s tyrosine kinase (BTK) inhibitors was a milestone in the treatment of B-cell malignancies in recent years owing to its desired efficacy against chronic lymphocytic leukaemia and small cell lymphocytic lymphoma. However, safety issues have hindered its application in clinical practice. The current study aimed to explore the safety warning signals of BTK inhibitors in a real-world setting using the FDA Adverse Event Reporting System (FAERS) to provide reference for clinical rational drug use.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Owing to the short marketing time of other drugs (zanbrutinib and orelabrutinib), we only analysed ibrutinib and acalabrutinib in this study. All data were obtained from the FAERS database from January 2004 to December 2021. Disproportionality analysis and Bayesian analysis were utilised to detect and assess the adverse event (AE) signals of BTK inhibitors.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> In total, 43,429 reports of ibrutinib were extracted and 1527 AEs were identified, whereas 1742 reports of acalabrutinib were extracted and 220 AEs were identified by disproportionality analysis and Bayesian analysis. Among reports, males were more prone to develop AEs (58.2% for males vs. 35.6% for females treated with ibrutinib, and 55.9% vs. 31.9%, respectively, for acalabrutinib), and more than 30% of patients that suffered from AEs were over 65\u00a0years of age. Subsequently, we investigated the top 20 preferred terms (PTs) associated with the signal strength of ibrutinib and acalabrutinib, and our results identified 25 (13 vs. 12, respectively) novel risk signals. Among the top 20 PTs related to death reports, the terms infectious, pneumonia, pleural effusion, fall, asthenia, diarrhoea, and fatigue were all ranked high for these two BTK inhibitors. Further, cardiac disorders were also an important cause of death with ibrutinib.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Patients treated with ibrutinib were more prone to develop AEs than those treated with acalabrutinib. Importantly, infection-related adverse reactions, such as pneumonia and pleural effusion, were the most common risk signals related to high mortality associated with both BTK inhibitors, especially in elderly patients. Moreover, cardiovascular-related adverse reactions, such as atrial fibrillation and cardiac failure, were fatal AEs associated with ibrutinib. Our results provide a rationale for physicians to choose suitable BTK inhibitors for different patients and provide appropriate monitoring to achieve safer therapy and longer survival.<\/jats:p>","DOI":"10.3389\/fphar.2022.995522","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T05:56:20Z","timestamp":1668146180000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":23,"title":["Data mining and safety analysis of BTK inhibitors: A pharmacovigilance investigation based on the FAERS database"],"prefix":"10.3389","volume":"13","author":[{"given":"Qing","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1182\/blood-2003-04-1142","article-title":"Tec regulates platelet activation by GPVI in the absence of Btk","volume":"102","author":"Atkinson","year":"2003","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"'Targeting B cell receptor signalling in cancer: Preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"B3","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"'acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood-2018-08-870238","article-title":"'Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab","volume":"133","author":"Byrd","year":"2019","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1182\/blood.2018884940","article-title":"'acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: Updated phase 2 results","volume":"135","author":"Byrd","year":"2020","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40265-021-01482-5","article-title":"'Orelabrutinib: First approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"B9","doi-asserted-by":"publisher","first-page":"630942","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects","volume":"9","author":"Estupinan","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"'Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1182\/blood-2017-11-818286","article-title":"'Early-onset invasive aspergillosis and other fungal infections in patients treated with ibrutinib","volume":"131","author":"Ghez","year":"2018","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"'ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: The CLARITY study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.hrthm.2019.04.008","article-title":"Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium","volume":"16","author":"Jiang","year":"2019","journal-title":"Heart rhythm."},{"key":"B16","doi-asserted-by":"publisher","first-page":"113329","DOI":"10.1016\/j.ejmech.2021.113329","article-title":"'Emerging small-molecule inhibitors of the Bruton's tyrosine kinase (BTK): Current development","volume":"217","author":"Liu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"'ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1056\/NEJMc1901284","article-title":"'ibrutinib regimens in older patients with untreated CLL","volume":"380","author":"Mercier","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/2162-3619-3-4","article-title":"'ibrutinib for B cell malignancies","volume":"3","author":"Novero","year":"2014","journal-title":"Exp. Hematol. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"'Single-agent ibrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia: A 5-year experience","volume":"131","author":"O'Brien","year":"2018","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"'Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal","year":"2018","journal-title":"Mol. Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","article-title":"'Management of adverse effects\/toxicity of ibrutinib","volume":"136","author":"Paydas","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/s0960-9822(98)70471-3","article-title":"'A role for Bruton's tyrosine kinase (Btk) in platelet activation by collagen","volume":"8","author":"Quek","year":"1998","journal-title":"Curr. Biol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.3324\/haematol.2020.272500","article-title":"'Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"106","author":"Rogers","year":"2021","journal-title":"Haematologica"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"'Cardiovascular toxicities associated with ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"Ca. Cancer J. Clin."},{"key":"B30","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1182\/blood-2020-140172","article-title":"'Pooled analysis of safety data from clinical trials of orelabrutinib monotherapy in hematologic malignancies","volume":"136","author":"Song","year":"2020","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4802","DOI":"10.1182\/bloodadvances.2020002183","article-title":"'Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma","volume":"4","author":"Tam","year":"2020","journal-title":"Blood Adv."},{"key":"B34","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.3324\/haematol.2020.259432","article-title":"'Zanubrutinib monotherapy for patients with treatment naive chronic lymphocytic leukemia and 17p deletion","volume":"106","author":"Tam","year":"2020","journal-title":"Haematologica"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e107041","DOI":"10.1371\/journal.pone.0107041","article-title":"'Erbb2 is required for cardiac atrial electrical activity during development","volume":"9","author":"Tenin","year":"2014","journal-title":"PLoS One"},{"key":"B36","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"Ca. Cancer J. Clin."},{"key":"B37","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","article-title":"'Inhibitors targeting bruton's tyrosine kinase in cancers: Drug development advances","volume":"35","author":"Wen","year":"2021","journal-title":"Leukemia"},{"key":"B38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.6004\/jnccn.2020.0006","article-title":"'Chronic lymphocytic leukemia\/small lymphocytic lymphoma, version 4.2020, NCCN clinical practice guidelines in Oncology","volume":"18","author":"Wierda","year":"2020","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"B39","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"'ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-016-0250-9","article-title":"Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor","volume":"9","author":"Wu","year":"2016","journal-title":"J. Hematol. Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13045-020-00884-4","article-title":"'Treatment of relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: Phase 2, single-arm, multicenter study","volume":"13","author":"Xu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"650","DOI":"10.6004\/jnccn.2019.0029","article-title":"'NCCN guidelines insights: B-cell lymphomas, version 3.2019","volume":"17","author":"Zelenetz","year":"2019","journal-title":"J. Natl. Compr. Canc. Netw."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.995522\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T05:56:24Z","timestamp":1668146184000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.995522\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":34,"alternative-id":["10.3389\/fphar.2022.995522"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.995522","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]},"article-number":"995522"}}